Gå direkt till innehåll

Nyhetsarkiv

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment


Press release

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment
CAMBRIDGE, UK; GOTHENBURG, Sweden – 29 November 2023 – Camallergy, a pioneer in developing oral immunotherapy treatments for food allergies, and OnDosis, a leader in intelligent dosing of oral solid medicines, are excited to announce a strategic collaboration.
This

New agreement expands collaboration between OnDosis and Tiefenbacher Group, paving way for a revolution in how patients with rare disease take their medicines

New agreement expands collaboration between OnDosis and Tiefenbacher Group, paving way for a revolution in how patients with rare disease take their medicines


Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.
Tiefenbacher Group is a pioneering healthcar

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing  integration of medicines and digital health

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. The collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines, digital therapeutics and intelligent dosing.

OnDosis – Changing the game, one dose at a time

Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.

OnDosis AB
Pepparedsleden 1
431 50 Mölndal
Sweden